Announcements

List of articles in category Announcements
Title Published Date
Verseon announces security token offering March 18, 2019
Verseon presents low bleeding PROACs at ISC 2019 February 11, 2019
First participant dosed in Verseon clinical trial February 4, 2019
BlockRules enters agreement with Neuseren October 11, 2018
Verseon unveils new blockchain technology September 18, 2018
Verseon commences anticoagulant phase I trial September 13, 2018
Interim Results 2018 August 8, 2018
Verseon submits phase I protocol for precision oral anticoagulant VE-1902 to regulatory authorities July 18, 2018
Annual Report for the Year Ended December 31, 2017 June 25, 2018
Verseon presents anticoagulants at BIO 2018 June 7, 2018
Verseon presents DME efficacy data at ARVO 2018 May 2, 2018
Verseon presents anticancer agents at AACR 2018 April 18, 2018
Verseon presents hereditary angioedema program at Biotech Showcase January 10, 2018
Verseon presents second anticoagulant candidate November 14, 2017
Verseon presents anticancer agents at BIO-Europe November 8, 2017
Verseon presents new DME efficacy results October 2, 2017
Interim Results 2017 September 25, 2017
Verseon presents preclinical data on diabetic macular edema candidates at BIO 2017 June 26, 2017
Verseon to present preclinical data on diabetic macular edema program and update on anticoagulation program at BIO 2017 June 9, 2017
Unique mechanism of action of Verseon’s novel class of anticoagulants to be presented at American Chemical Society meeting March 30, 2017
Verseon to showcase low bleeding risk anticoagulation candidates at BIO-Europe Spring March 20, 2017
Annual Report for the Year Ended December 31, 2016 March 13, 2017
Verseon granted US patents covering its novel serine protease inhibitors January 4, 2017
ASH 2016: Explaining the lower bleeding risk of Verseon’s anticoagulants December 6, 2016
Preclinical research to be presented at ASH Annual Meeting shows Verseon’s new class of anticoagulants prevents thrombosis while preserving platelet function November 23, 2016
Verseon to Present New Preclinical Safety and Tolerability Results at the 2016 American Heart Association’s Scientific Sessions November 14, 2016
Interim Results September 5, 2016
Verseon to Present Latest Anticoagulant Results at Bio 2016 June 6, 2016
Verseon to Present Additional Preclinical Results at BioEurope Spring 2016 conference April 4, 2016
Annual Report for the Year Ended 31 December 2015 March 7, 2016
Verseon Presents Low Bleeding Risk Anticoagulants at International Medical Conference February 28, 2016
Verseon to Present New Preclinical Results for Novel Class of Oral Anticoagulants at the 3rd International Conference on Heart & Brain February 10, 2016
Verseon to Present Data on a New Class of Anticoagulants January 12, 2016
Interim Results for the Six Months Ended 30 June 2015 September 7, 2015
Verseon Acquires Research and Development Facility August 20, 2015
Annual Report for the Year Ended 31 December 2014 June 29, 2015
First Day of Dealings May 7, 2015

Proprietary Platform

Consistently designs novel drug candidates that are unlikely to be found using conventional methods

 

Drug Programs

Multiple therapeutic areas, all with unmet (or poorly met) medical needs